Subtype
Lung Non-Small Cell Carcinoma with Genetic Abnormalities
CI-CAN-00005823Explore in graph →
10 active trials4 approved drugs
- NCIt
- C227212
Loading cancer entity…
Subtype
CI-CAN-00005823Explore in graph →
Clinical trials
31 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (5)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04211922 | Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib | terminated | Phase 2 | 4 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Apr 26, 2024 | clinicaltrials |
| NCT02513667 | Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma | terminated | Phase 2 | 14 | University of Texas Southwestern Medical CenterOTHER | 1 | Feb 3, 2023 |
| clinicaltrials |
| NCT03131206 | A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer | terminated | Phase 1 / Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 27, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Apr 26, 2024source: clinicaltrials